View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

       

News

Regeneus Ltd (ASX:RGS) to be granted new key Progenza patent in U.S.

🕔3/23/2020 9:42:44 AM 709

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's lead stem cell platform technology, Progenza, in the U.S.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives A$1.6M Milestone Payment from Kyocera

🕔3/20/2020 9:49:10 AM 904

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, Today received a non-refundable milestone payment of 100,000,000 JPY (approx. A$1.6M) from Kyocera Corporation (TYO:6971) as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.

Read Full Article

Regeneus Ltd (ASX:RGS) Signs MOU with Kyocera Corporation

🕔3/2/2020 10:23:45 AM 1333

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has signed a non-binding MOU with Kyocera Corporation (Kyocera, TYO:6971).

Read Full Article

Regeneus Ltd (ASX:RGS) Half-Year Results & Business Update

🕔2/28/2020 4:16:21 PM 1297

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its Half-Year Financial Results and Appendix 4D for the period ended 31 December 2019 (H1 FY20).

Read Full Article

Regeneus Ltd (ASX:RGS) Directors Provide $4m Loan Facility

🕔2/28/2020 4:09:21 PM 1046

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced its Board of Directors has put in place loan facilities totalling $4 million to extend the Company's funding runway to support negotiations to license and commercialise Progenza for knee osteoarthritis (Progenza OA) in Japan.

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4C - Quarterly

🕔1/31/2020 9:48:10 AM 2505

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its quarterly cashflow report and review of operational activities for the period ending 31 December 2019 (Q2 FY20).

Read Full Article

Regeneus Ltd (ASX:RGS) AGC Agreement Termination Paves Way for Commercial Partner

🕔12/20/2019 10:33:02 AM 2895

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc to terminate their exclusive manufacturing licence and joint venture agreement.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives Innovation Grant

🕔12/18/2019 10:48:37 AM 1998

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has received $50K in funding as part of the Innovation Connections Grant from the Australian Government's Department of Industry, Innovation and Science.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders and CEO AGM Presentation

🕔11/21/2019 3:15:30 PM 1588

2019 was a productive year as we continued our aim of commercialising Progenza and Sygenus, our core regenerative medicine technology platforms. In particular, our focus has been on the lead platform, Progenza, which has shown positive results for treating osteoarthritis in its Phase 1 trials.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Biotech Fund takes up all Rights Issue Shortfall

🕔11/19/2019 10:40:44 AM 1672

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has placed the full shortfall of 9,437,872 shares under its recent Non-Renounceable Rights Issue. The shortfall was placed to a Japan-based institutional investor at an issue price of A$0.08 per share for a total of A$755,029.

Read Full Article
###

135,567 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 345) (Last 30 Days: 1603) (Since Published: 63907) 

Company Data

    Headquarters
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports